Is celiac disease having a significant impact on your daily life? You may be eligible for a clinical study.
What is the ASPIRION clinical study?
The ASPIRION study is a phase 2 study looking into a new, investigational study drug (amlitelimab) for patients with celiac disease. The aim of the study is to see whether the investigational study drug, in combination with a gluten-free diet, can reduce the damage in the small intestine and what effect it has on the symptoms caused by celiac disease.
Compensation may be available.
Who can participate?
The ASPIRION study is looking for patients with celiac disease who continue to have symptoms despite following a gluten-free diet. You may be eligible* to participate in the study if you:
- Are between 18 – 75 years old
- Have a medical diagnosis of celiac disease
- Have been on a gluten-free diet for at least 12 months but are still experiencing symptoms
*Please note there are more eligibility criteria that must be met to be considered for participation.
Learn more: celiac.org/aspirion-us
Obtenga más información: celiac.org/aspirion-us-es
ASPIRION Celiac Disease Clinical Trial